Literature DB >> 14631578

[Therapy and prophylaxis of renal failure].

V M Brandenburg1, B Heintz, J Floege.   

Abstract

The number of patients with end-stage renal disease is constantly growing. If patients at risk are identified early enough, currently available therapeutic options allow a potent primary and secondary prevention of progressive renal failure. If the underlying disease can not be eliminated, the mainstay of the therapy are supportive measures such as antihypertensive and, in case of an underlying diabetes mellitus, antidiabetic therapy, dietary restrictions as well as avoidance of additional nephrotoxic agents. Furthermore, even a mild renal insufficiency has been identified as a potent cardiovascular risk factor. The second major goal of supportive therapy therefore is a reduction of the markedly increased cardiovascular morbidity of these patients. This can be achieved through treatment of various consequences of renal failure, such as hyperparathyroidism, renal anemia etc. Supportive therapy thus represents a highly complex and interdisciplinary treatment, which should prompt an early inclusion of a nephrologist into the therapeutic strategy.

Entities:  

Mesh:

Year:  2003        PMID: 14631578     DOI: 10.1007/s00108-003-0948-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  103 in total

1.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.

Authors:  P Gaede; P Vedel; H H Parving; O Pedersen
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis.

Authors:  P Weidmann; M Schneider; L Böhlen
Journal:  Nephrol Dial Transplant       Date:  1995-10       Impact factor: 5.992

3.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 5.  Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring.

Authors:  R L Slaughter; D M Cappelletty
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

6.  Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study.

Authors:  Samy Hadjadj; Riadh Belloum; Béatrice Bouhanick; Yves Gallois; Gérard Guilloteau; Gilles Chatellier; François Alhenc-Gelas; Michel Marre
Journal:  J Am Soc Nephrol       Date:  2001-03       Impact factor: 10.121

7.  Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks?

Authors:  Carlo Meloni; Massimo Morosetti; Concetta Suraci; Maria G Pennafina; Carmela Tozzo; Massimo Taccone-Gallucci; Carlo U Casciani
Journal:  J Ren Nutr       Date:  2002-04       Impact factor: 3.655

8.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.

Authors:  J T Kielstein; R H Böger; S M Bode-Böger; J Schäffer; M Barbey; K M Koch; J C Frölich
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

9.  Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study.

Authors:  Markus Ketteler; Philipp Bongartz; Ralf Westenfeld; Joachim Ernst Wildberger; Andreas Horst Mahnken; Roland Böhm; Thomas Metzger; Christoph Wanner; Willi Jahnen-Dechent; Jürgen Floege
Journal:  Lancet       Date:  2003-03-08       Impact factor: 79.321

10.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.

Authors:  Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

View more
  2 in total

1.  [Therapeutic strategies to prevent chronic kidney disease progression].

Authors:  B M W Schmidt
Journal:  Internist (Berl)       Date:  2012-07       Impact factor: 0.743

Review 2.  [IgA nephropathy: frequent, but rarely diagnosed].

Authors:  J Floege; H-J Gröne
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.